Your Hairline Is Changing.
No Prescription Required
to Address It Clinically.
Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S. alone.1 The standard options are well-known — and so are their limitations. This is the plant-based system that works on the follicle environment without finasteride, without minoxidil, without a prescription.
See the Home Treatment →The Crown. The Part.
The Hairline. Always Gradual.
Never Welcome.
Pattern hair loss moves slowly — which is exactly what makes it so insidious. By the time you notice, months or years of gradual follicle miniaturization have already happened. The biology is well understood: DHT (dihydrotestosterone) binds to receptors in genetically susceptible follicles, shortening the growth phase until the follicle produces progressively finer, shorter hair. Once miniaturization is far advanced, reversal is significantly harder.
The window for intervention matters. The goal is always to address it while follicles are still active — not after they've stopped.
This page is educational information about cosmetic scalp and hair care. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Individual results vary. See a physician or dermatologist about hair loss, and before making any change to prescribed treatment.
On April 22, 2025, the U.S. Food and Drug Administration issued an alert about compounded topical finasteride — the formulation sold through many telehealth services — citing 32 adverse-event reports received between 2019 and 2024, including erectile dysfunction, decreased libido, anxiety, depression and suicidal ideation, with most reported to persist after the product was stopped. Worth knowing: there is no FDA-approved topical finasteride. Every topical version is compounded.4
Oral finasteride has its own regulatory history: depression was added to the U.S. label in 2011 and suicidal ideation in 2022. In Europe, a 2025 decision strengthened warnings for both the 1 mg and 5 mg tablets.5 Context matters here, and we'd rather give it than not: those European warnings followed roughly 313 reported cases against an estimated 270 million patient-years of exposure, and the regulator's own conclusion was that the benefits of finasteride still outweigh its risks.
So this is not a reason to dismiss finasteride, which remains effective for the right patient under physician guidance. It is a reason why a meaningful and growing number of men and women with pattern hair loss are specifically looking for a non-pharmaceutical option — and why that option should be honest about what it is.
DHT Is the Driver.
The Follicle Environment Is What Can Be Supported.
No plant-based system blocks DHT the way finasteride or dutasteride do — and this page won't claim otherwise. What the Kapyderm system does is support the scalp environment that miniaturizing follicles sit in: blood supply, nutrient delivery, a clear follicular opening, and the internal nutritional foundation hair tissue depends on.
How This Compares to
Standard Pattern Hair Loss Options
| Option | Category | Mechanism | Considerations |
|---|---|---|---|
| Oral Finasteride (Propecia) | FDA-approved drug | Blocks DHT via 5-alpha reductase inhibition. The most effective option for men. | Prescription only; sexual adverse effects reported in trials and post-marketing; label warnings added 2011 and 2022; not approved for most women⁵ |
| Topical Minoxidil (Rogaine 5%) | FDA-approved OTC drug | Increases scalp blood flow. Effective, and the strongest non-prescription option. | Scalp irritation is common; results reverse when discontinued; doesn't address internal factors³ |
| Oral supplement brands | Dietary supplement | Internal-only — botanical and micronutrient blends | No topical component; efficacy claims vary by brand and are not FDA-evaluated |
| Telehealth prescription services | FDA-approved drugs, prescribed remotely | Finasteride and/or minoxidil delivered by subscription | Prescription required; ongoing cost; the finasteride safety profile above applies, and compounded topicals carry the April 2025 FDA alert⁴⁶ |
| Kapyderm Pattern Hair Loss Treatment | Cosmetic scalp care + supplements | Topical follicle-environment support + internal nutrition — no DHT blockers | No prescription, no finasteride, plant-based and EU-regulated. Not a drug, and no controlled trial of this system exists. |
This compares categories and approaches rather than making claims about specific competing brands. Third-party formulas, pricing and terms change without notice — check them directly. No head-to-head trial of this system against any of these options exists.
Pattern Hair Loss Presents
Differently in Men and Women
The Pattern Hair Loss Home Treatment
No finasteride. No minoxidil. No prescription. Plant-based, EU-regulated formulas addressing follicle microcirculation, scalp environment, and internal nutrition together.
Revital and Shock Ecology are dietary supplements. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Tell your physician about any supplement you add, particularly alongside prescription treatment.
Two-Phase Protocol
- Nightly: Apply Alogenic Tonic (2ml) to scalp · Take 2 Shock Ecology capsules
- 3× per week: Apply Ampoule DT to affected areas
- Daily wash: Hair Loss Base Cleanser
- Morning + Afternoon: Take 2 Revital capsules each time
- 3× per week: Apply Alogenic Tonic to scalp
- 3-month cycles: Continue Shock Ecology capsules
- Daily wash: Continue Hair Loss Base Cleanser
What to Expect — A Realistic Timeline
This is a general guide, not a guarantee. Individual results vary, and pattern hair loss is progressive — no cosmetic system stops the underlying hormonal mechanism.
What Practitioners Are Seeing
A practitioner's clinical impression, not a controlled comparison. Individual results vary.
Frequently Asked Questions
Your Follicles Are Still Active.
Let's Keep Them That Way.
The Pattern Hair Loss Home Treatment supports follicle microcirculation, clears scalp congestion, and addresses the internal nutritional factors that standard topicals miss — without a prescription, without finasteride.
Plant-based · EU-regulated · No finasteride · No prescription
- American Academy of Dermatology, hair loss statistics; and Peyravian N, et al. The Inflammatory Aspect of Male and Female Pattern Hair Loss. J Inflamm Res. Approximately 80 million Americans — about 50 million men and 30 million women — are affected by androgenetic alopecia.
- Ho CH, Sood T, Zito PM. Androgenetic Alopecia. / Male Androgenetic Alopecia, Endotext, NCBI Bookshelf. Approximately 30–50% of men develop pattern hair loss by age 50, with prevalence and severity rising with age. NBK278957
- Androgenetic Alopecia — clinical overview. Only two drugs hold FDA-approved indications for androgenetic alopecia: minoxidil and finasteride. Prevalence in women rises substantially after menopause. Medscape reference
- U.S. Food and Drug Administration. Public safety alert on compounded topical finasteride, April 22, 2025 — 32 adverse-event reports received 2019–2024; no FDA-approved topical finasteride product exists. fda.gov
- FDA labeling history for oral finasteride (depression added 2011; suicidal ideation added 2022) and European Commission implementing decision C(2025) 5896 final, 22 August 2025, strengthening warnings for 1 mg and 5 mg finasteride — approximately 313 reported cases against an estimated 270 million patient-years of exposure, with the regulator concluding that benefits continue to outweigh risks.
- Adverse Events of Topical Finasteride for Male Androgenetic Alopecia: A Systematic Review. JAAD Int, 2025. FDA FAERS data 2019–2024. doi:10.1016/j.jdin.2025.01.003
6 cited sources. Regulatory statements are cited to the regulators themselves rather than to secondary coverage. No controlled trial of the Kapyderm Pattern Hair Loss Home Treatment exists, and no head-to-head trial against minoxidil, finasteride or any supplement brand exists.